ValuEngine Lowers Affimed (NASDAQ:AFMD) to Sell

Affimed (NASDAQ:AFMD) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, ValuEngine reports.

Several other research analysts have also issued reports on the company. Zacks Investment Research upgraded Affimed from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Tuesday, July 2nd. Laidlaw set a $10.00 price target on Affimed and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Affimed has an average rating of “Buy” and an average price target of $5.63.

Shares of NASDAQ:AFMD traded up $0.13 during midday trading on Thursday, hitting $2.96. The company had a trading volume of 1,063,162 shares, compared to its average volume of 639,256. Affimed has a 12 month low of $1.40 and a 12 month high of $7.35. The company has a current ratio of 3.17, a quick ratio of 3.16 and a debt-to-equity ratio of 0.03. The company has a market cap of $184.67 million, a PE ratio of -7.79 and a beta of 2.84. The business has a fifty day moving average of $3.03.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.19. Affimed had a negative return on equity of 23.61% and a negative net margin of 29.04%. The business had revenue of $12.89 million for the quarter, compared to analyst estimates of $6.77 million. On average, sell-side analysts forecast that Affimed will post -0.28 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AFMD. Millennium Management LLC lifted its holdings in Affimed by 7.2% during the fourth quarter. Millennium Management LLC now owns 3,121,914 shares of the biopharmaceutical company’s stock worth $9,709,000 after acquiring an additional 210,884 shares in the last quarter. Acadian Asset Management LLC bought a new position in Affimed during the first quarter worth about $253,000. Deutsche Bank AG lifted its holdings in Affimed by 2,243.6% during the fourth quarter. Deutsche Bank AG now owns 49,074 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 46,980 shares in the last quarter. MYDA Advisors LLC lifted its holdings in Affimed by 150.0% during the first quarter. MYDA Advisors LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Affimed by 35.6% during the fourth quarter. Barclays PLC now owns 76,959 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 20,196 shares in the last quarter. Hedge funds and other institutional investors own 37.51% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Recommended Story: Buyback

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.